Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 1, 2004Internal MedicineOpen Access

Five Cases of Anthracycline-Induced Cardiomyopathy Effectively Treated with Carvedilol

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does carvedilol improve left ventricular function and symptoms in patients with anthracycline-induced cardiomyopathy?

Population

5 patients with newly diagnosed anthracycline-induced cardiomyopathy following chemotherapy for acute…

Design

Case_series

Authors

YMYasushi MukaiElectrophysiologyTYTomoki YoshidaHiroshima UniversityRNRyuichi NakaikeKyushu University

Discussion

Loading...

Member takes

Implication

May support carvedilol in anthracycline cardiomyopathy; hypothesis-generating from small case series and requires randomized confirmation.

Key Points

  • Evaluate the clinical efficacy of carvedilol in managing severe chronic heart failure caused by anthracycline-induced cardiomyopathy.
  • Reviewed clinical outcomes in a case series of 5 patients presenting with severe chronic heart failure secondary to anthracycline-induced cardiomyopathy.
  • Administered the beta-blocker carvedilol and monitored changes in clinical symptoms and left ventricular performance.
  • Carvedilol administration resulted in persistent improvement in left ventricular systolic function across all evaluated cases.
  • Patients achieved durable relief and marked alleviation of chronic cardiac symptoms following treatment.

Structured PICO

Does carvedilol improve left ventricular function and symptoms in patients with anthracycline-induced cardiomyopathy?

P
Population
5 patients with newly diagnosed anthracycline-induced cardiomyopathy (ACM) following chemotherapy for acute myelocytic leukemia, with persistent left ventricular dysfunction (mean LVEF 36%) despite conventional therapy.
I
Intervention
Carvedilol initiated at 1-2 mg/day and titrated up to 10-20 mg/day over months.
O
Outcome
Left ventricular function (LVEF and end-diastolic dimension via echocardiography) and cardiac symptoms (NYHA functional class)surrogate

In a small case series, carvedilol improved left ventricular ejection fraction and symptoms in patients with anthracycline-induced cardiomyopathy.

Limitations

  • Small number of patients

Cite This Study

Mukai et al. (2004) studied this question.

synapsesocial.com/papers/6a8374c83965fa42e1c94c15https://doi.org/10.2169/internalmedicine.43.1087

Topics

Heart failureHFrEF treatmentEchocardiographyCardiomyopathyCardiac amyloidosis
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The Role of Carvedilol in the Treatment of Dilated and Anthracyclines-Induced Cardiomyopathy2011 · 10 citations
  2. 2Protective Effects of Carvedilol Against Anthracycline-Induced Cardiomyopathy2006 · 715 citations
  3. 3Protective effect of carvedilol against anthracycline-induced cardiomyopathy on patients with breast cancer and lymphoma2018 · 5 citations
  4. 4Preventive role of carvedilol in adriamycin-induced cardiomyopathy2016 · 55 citations
  5. 5Protective Effect of Carvedilol in Cardiomyopathy Caused by Anthracyclines in Patients Suffering from Breast Cancer and Lymphoma2011 · 36 citations